Raffa: Beatrice went under the radar as they did not increase the dividend. Management was asked on the call about the dividend, it was a bit of a heated response to that. I think the company is doing the right things, first of all, because what the company has done it has sold its biosimilar business and a really, really attractive deal. But they are also transforming their portfolio. So there's some elevated risk there. Of course, as a dividend growth investor, I wanted to see dividend growth. Still they could have given us even a quarter of a cent a hike here and just bought the difference in the back.